On July 1, 2026, Can-Fite BioPharma Ltd. announced that its Phase 2a study of Namodenoson for pancreatic cancer achieved its primary safety endpoint and demonstrated durable survival outcomes in patients with advanced disease. The company operates in the biotechnology industry and develops therapeutic candidates for various diseases.
